Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth

American Journal of Pathology

Volumn 155, Issue 2, 1999, Pages 411-419

  Cool, Carlyne D ^a   Stewart, J Scott ^a   Werahera, Priya ^a   Miller, Gary J ^a   Williams, Randy L ^a   Voelkel, Norbert F ^a   Tuder, Rubin M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27; VASCULOTROPIN RECEPTOR;

ADULT; ARTICLE; CELL GROWTH; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; THREE DIMENSIONAL IMAGING;

EID: 0032777126     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65137-1     Document Type: Article

References (33)

1. Wagenvoort CA, Wagenvoort N: Primary pulmonary hypertension. A histopathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970, 42:1163-1184
2. Edwards, WD: Pathology of pulmonary hypertension. Cardiovasc Clin 1987, 18:321-354
3. Saunders JB, Constable TJ, Heath D, Smith P, Paton A: Pulmonary hypertension complicating portal vein thrombosis. Thorax 1978, 34: 281-283
4. Robalino BD, Moodie DS: Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991, 17:492-498
5. Thomas SH, Butt AY, Corris PA, Egan JJ, Higenbottam TW, Madden BP, Waller PC: Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Br Heart J 1995, 74:660-663
6. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G: Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993, 70:537-541
7. Petitpretz P, Brenot F, Azarian R, Parent F, Rain B, Herve P, Simonneau G: Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994, 89:2722-2727
8. Pietra GG: Histopathology of primary pulmonary hypertension. Chest 1994, 105:2S-6S
9. Pietra GG, Ruttner JR: Specificity of pulmonary vascular lesions in primary pulmonary hypertension. A reappraisal. Respiration 1987, 52:81-85
10. Ogata T, Iijima T: Structure and pathogenesis of plexiform lesion in pulmonary hypertension. Chin Med J 1993, 106:45-48
11. Yaginuma G, Mohr H, Takahashi T: Distribution of arterial lesions and collateral pathways in the pulmonary hypertension of congenital heart disease: a computer-aided reconstruction study. Thorax 1990, 45: 586-590
12. Heath D, Edwards JE: The pathology of hypertensive pulmonary vascular disease. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac defects. Circulation 1958, 18:533-547
13. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD: Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984, 70:580-587
14. Tuder RM, Groves B, Badesch DB, Voelkel NF: Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994, 144:275-285
15. Cool CD, Kennedy D, Voelkel NF, Tuder RM: Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997, 28:434-442
16. Haworth SG, Rabinovitch M, Meyrick B, Michel R, Pietra GG, Polak JM, Reid LM, Tuder R: The pathology of pulmonary hypertension. Primary Pulmonary Hypertension: Executive Summary from the World Symposium-Primary Pulmonary Hypertension 1998. Edited by S Rich. (Available from the World Health Organization via the Internet (http://www.who.int/ncd/cvd/pph.html).)
17. Loscalzo J: Endothelial dysfunction in pulmonary hypertension. N Engl J Med 1992, 327:70-75
18. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch DB, Voelkel NF: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159:1925-1932
19. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333:214-221
20. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Steward DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739
21. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF: 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1998, 157:219-229
22. Lee S-D, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM: Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998, 101:927-934
23. Tuder RM, Radisavljevic Z, Shroyer KR, Polak JM, Voelkel NF: Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med 1998, 158:1999-2001
24. Folkman J, D'Amore PA: Blood vessel formation: what is its molecular basis? Cell 1996, 87:1153-1156
25. Risau W: Differentiation of endothelium. FASEB J 1995, 9:926-933
26. kip1 expression is inversely proportional to the proliferative index Am J Pathol 1997, 151:151-160
27. Kato J, Matsuoka M, Polyak K, Massague J, Sherr CJ: Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27KIP1) of cyclin-dependent kinase 4 activation. Cell 1994, 79:487-496
28. kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994, 372:570-573
29. Patterson C, Perrella MA, Hsieh C-M, Yoshizumi M, Lee M-E, Haber E: Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem 1995, 39:23111-23118
30. Waltenberger J, Claesson-Welsh L, Siegbahn A, Masabumi S, Heldin C-H: Different signal transduction properties of KDR and FIt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269:26988-26995
31. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25
32. Jamison BM, Michel RP: Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. Hum Pathol 1995, 26:987-993
33. Pietra GG: The pathology of primary pulmonary hypertension. Primary Pulmonary Hypertension. Lung Biology in Health and Disease, vol 99. Edited by LJ Rubin and S Rich. New York, Marcel Dekker, 1997, pp 19-61